.... For the systematic review, among 3,053 reports screened, 217 were included involving 1,189 patients (1,143 received sirolimus, 38 everolimus, 4 alpelisib, 4 miransertib). Among the 1,189 cases, 2 (0.2%) PJP were reported: one under sirolimus and one under everolimus. Thus, the prevalence of PJP was estimated at 0.88...

...Young In Lee; Ju Hee Lee; Do Young Kim; Kee Yang Chung; Jung U. Shin Background: Recent reports have suggested that the topical formulation of sirolimus is effective in treating facial angiofibromas in tuberous sclerosis complex (TSC). Here, we determined the safety and efficacy of 0.2% topical...

...J. Lübbe; O. Sorg; P.-J. Malé; J.-H. Saurat; I. Masouyé Sirolimus is an immunosuppressive macrolide with antineoplasic properties that is increasingly used in posttransplantation immunosuppression. The treatment is frequently associated with cutaneous side effects such as sirolimus-associated...

..., the responsibility of immunosuppressive agents given to transplant recipients in the development of angioedema has been discussed. Objective: To describe, in detail, angioedema episodes in renal transplant recipients (RTRs) on sirolimus. Methods: A cross-sectional study in a university hospital. Eighty consecutive...

... of vascular endothelial growth factor (VEGF) andup-regulation of VEGF receptor, KDR, in endothelial cells. We report a case of KS in a 72-year-old male with a renal transplant who had received immunosuppressant drugs including sirolimus, mycophenolate mofetil, tacrolimus and steroids. KS developed 11 months...

...N. Kunzle; J.-P. Venetz; M. Pascual; R.G. Panizzon; E. Laffitte Sirolimus is a new immunosuppressive agent used to prevent rejection in renal allograft recipients in order to reduce the need of potentially nephrotoxic calcineurin inhibitors (cyclosporine, tacrolimus). The cutaneous side effects...